Artialis Group is a CRO specialized in the development of therapies and biomarkers in the field of musculoskeletal disorders, including osteoarthritis, sarcopenia, tendinopathies, and intervertebral disk degeneration. The core service of Artialis’ technological platform is the biotesting of biomarkers for musculoskeletal diseases. They exclusively offer quantification of two proprietary biomarkers, COLL2-1 and COLL2-1NO2. Those are degradative fragments of type-II collagen, classified as biomarkers of osteoarthritis. In addition, the company offers testing of any commercially available ELISA and/or multiplex kit after a strict internal validation of its performance to ensure robustness and the reproducibility of the result

Artialis is unique because it is the only CRO in this field that offers a complete “all-in one” solution allowing customers to have only one partner for the different development phases of their product—from preclinical to post marketing clinical trials

—Yves Henrotin, President and CEO

Eurofins Scientific is an international life sciences company providing a unique range of analytical testing services to clients across multiple industries to make life and the environment safer, healthier and more sustainable. Eurofins works with the biggest companies globally to ensure the products they supply are safe, their ingredients are authentic, and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences, and in support of clinical studies

The wide range of high-quality services is in coherence with Eurofins’ vision to provide its customers with innovative services that help them grow and enhance their drug development processes

Dr Gilles Martin, Chairman of the Board and Chief Executive Officer

ICON offers a full range of consulting, development and commercialisation services that enable pharmaceutical, biotechnology, medical device, and government and public health organisations to accelerate the development of drugs and devices. The company develops integrated technologies to significantly enhance the efficiency and productivity of its clients’ drug and device development programs, providing true transparency across all areas of a study. Further, ICON’s information hub, ICONIK analyses the operational, clinical, and real-world data collected during clinical development that enhances the design and delivery of projects and strengthens engagement with investigators and patients

The company develops integrated technologies to significantly enhance the efficiency and productivity of its clients’ drug and device development programs, providing true transparency across all areas of a study

—Dr. Steve Cutler, CEO

Intravacc has an extensive track record in developing vaccines for infectious diseases, positioning the company as a leading vaccine biotech company. The core team of Intravacc is known to have assisted a number of government bodies around the world in the past in developing life-saving vaccines for diseases like polio, measles, DPT, Hib, and influenza. After its recent privatisation, Intravacc is now pushing its bounds towards a more commercial future, so that it can support international academic institutions, public health organisations (WHO, BMGF), and pharmaceutical companies to take their vaccines to late-stage clinical trials. And at the heart of these efforts lie three proprietary platforms—cell-based, OMV-based, and the conjugation platform–developed by Intravacc. These platforms are taking the mantle in helping reduce the time and cost factors while developing new vaccines

In addition to developing its own vaccine candidates, Intravacc also partners with biotech and pharma companies as a CDMO

—Dr. Jan Groen, CEO and Chairman of the Board

Offers drug development services, early clinical services, pharmaceutical development services, packaging and distribution services, bioanalytical services, and formulation services

Arcinova, a Quotient Sciences company, delivers high-quality end-to-end solutions by combining the disciplines of chemistry, biology, and bioinformatics and provides the pharmaceutical industry with integrated and specialist services throughout the drug development pipeline. The company focuses on process, research, development, scale-up and small-scale manufacturing, including best-in-class technology, bioanalysis, regulatory, and consulting services. As a trusted partner for its customers, the firm supports their development and delivery programmes for new medicines in a timely and cost-effective manner to sustainably improve the health and wellbeing of society

We do not see it as a service. It is more of a collaboration

—Stuart McDougall, Head of Bioanalytical Services

SGS offers many approved tests, including cell- and Immuno ligand-based assays, as well as potency assay testing methodologies. From early phase cell bank safety assessment and product characterization to later phase method development, bioanalysis, and final phase product release, the company delivers innovative biopharmaceutical testing, biosafety, bioanalytics, and product quality control solutions for every lifecycle stage

Our value to society is enabling a better, safer and more interconnected world

—Frankie Ng, CEO

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle. The company's innovative services range from R&D, biomarker discovery, development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) to commercial-scale manufacture. Over the past five decades, this privately-owned company has grown organically and now employs over 6,000 highly skilled personnel across 18 facilities, including Europe, the US, and Asia

LGC is a global leader in the life science tools sector, providing mission critical components to customers across clinical diagnostics, pharmaceutical, research & government, food, and other applied markets. LGC's product catalogue includes mission-critical tools for genomic analysis and quality assurance applications valued for their performance, quality and range. The tools play a primary role in customer workflows from discovery applications to commercial manufacture and allow customers to introduce new diagnostics and therapies to market, improve research and development, optimise food production. These help to monitor and improve the quality of food, environment and consumer products

Lipotype's Lipotype Shotgun Lipidomics provides lipidomics analysis of more than 3100 lipids and absolute quantification of lipid species. This helps to identify and quantify thousands of lipids rapidly. Further, Lipotype's mass spectrometry-based technology was designed to adapt to a wide variety of sample types to reflect the diversity of research. The company's scientific curiosity steers them to continually upgrade their lipidomics technology and serve the scientific community to achieve the greater goal of life sciences a better life